Results 131 to 140 of about 19,292 (214)

Chronic Bilateral Anterior Shoulder Fracture-Dislocation Following Febrile Seizure After COVID-19 Vaccine: A Case Report. [PDF]

Cureus, 2023
AlAskar B, Alqahtani A, Alsuhaim S.
europepmc   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

The Effects of 6-Month Exclusive Breastfeeding on Febrile Seizure: A Systematic Review and Meta-Analysis. [PDF]

Iran J Child Neurol
Vard B, Yazdi M, Akbarzadeh Z, Rouzbahani S, Kelishadi R.   +4 more
europepmc   +1 more source

Children with COVID-19 Who Manifest Febrile Seizure. [PDF]

Case Rep Med, 2021
Dewiyanti L, Sumarni N, Lie JD, Hidajati Z, Kahayana HP, Lukmasari A, Pramana C.   +6 more
europepmc   +1 more source

Drug‐Refractory Dystonia: Benefits of Lamotrigine Therapy in a Case of SCN2A Epilepsy‐Dyskinesia Syndrome

Movement Disorders Clinical Practice, EarlyView.
Isobel S. Platt, Patrick B. Moloney, Sanjay M. Sisodiya, Thomas T. Warner   +3 more
wiley   +1 more source

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

Cancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba, Toshihiro Miyamoto, Senji Kasahara, Yoshikane Kikushige, Takahiro Maeda, Goichi Yoshimoto, Shuichi Ota, Akio Saito, Yuho Najima, Hiroki Hosoi, Daigo Niiya, Koji Kato, Koji Nagafuji, Takashi Akasaka, Tomohiko Kamimura, Atsushi Takita, Maiko Narahara, Tadashi Toki, Koichi Iwanaga, Koji Yonemoto, Mine Harada, Koichi Akashi   +21 more
wiley   +1 more source

Unveiling the Uncommon: Roseomonas gilardii Bacteremia in a 10-Month Infant Presenting With Febrile Seizure. [PDF]

Cureus
Purushotham P, Mahapatra A, Jafri N, Satapathy A.   +3 more
europepmc   +1 more source

Deep Phenotyping in ReNU Syndrome Identifies a Recognizable Age‐Dependent Clinical Trajectory

Clinical Genetics, EarlyView.
Longitudinal evaluation of 11 individuals with ReNU syndrome revealed an age‐dependent multisystem trajectory. This longitudinal description may help clinicians anticipate changing needs in feeding, growth, neurological, visual, communication, behavioral, and orthopedic care. ABSTRACT Pathogenic variants in the noncoding gene RNU4‐2 cause ReNU syndrome,
Nadja Pekkola Pacheco, Malin Kvarnung, Anna Hammarsjö, Daniel Nilsson, Bianca Tesi, Britt Marie Anderlid, Giedre Grigelioniene, Maria Johansson Soller, Liselot van der Laan, Charlotte Willfors, Charlotta Ingvoldstad Malmgren, Anna Lindstrand, Tommy Stödberg, Ann Nordgren, Angelica Maria Delgado‐Vega   +14 more
wiley   +1 more source

A rare and devastating etiology of febrile seizure. [PDF]

Ann Child Neurol Soc
Pia S, Stackhouse E, Ellika S.
europepmc   +1 more source

Challenges in Gene‐Directed Therapies for Rare Neurodevelopmental Disorders Using HNRNPU as an Exemplar

Clinical Genetics, EarlyView.
Beyond diagnosing rare neurodevelopmental disorders like HNRNPU‐RNDD, developing gene‐directed therapies requires overcoming complex hurdles, including spatial, developmental, and cell‐type constraints. Addressing these requires understanding the molecular effects of dosage and chromatin dynamics to deliver precise, effective treatments.
Daniel Aiyedun, Susan F. Rogers, Doaa M. Taha, Meena Balasubramanian   +3 more
wiley   +1 more source